Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort [0.03%]
一项多中心队列研究：生活在HIV环境中的绝经前和绝经后女性接受抗逆转录病毒治疗的有效性和安全性
Belén Alejos,Inés Suárez-García,Jose Ignacio Bernardino et al.
Belén Alejos et al.
Background: To compare effectiveness and safety of initial antiretroviral therapy (ART) among premenopausal and postmenopausal women living with HIV aged 45-60 years from the cohort of the Spanish HIV/AIDS Research Networ...
Multicenter Study
Antiviral therapy. 2020;25(6):335-340. DOI:10.3851/IMP3380 2020
An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia [0.03%]
扩大了的艾滋病关怀进程：亚洲地区HIV感染者的抗病毒治疗、病毒载量抑制以及伴随疾病监测情况
Rimke Bijker,Nagalingeswaran Kumarasamy,Sasisopin Kiertiburanakul et al.
Rimke Bijker et al.
Background: Comprehensive treatment and clinical management are central to improving outcomes for people living with HIV (PLHIV). We explored trends in HIV clinical care, treatment outcomes, and chronic kidney disease (CK...
Weight gain during pregnancy in women with HIV receiving different antiretroviral regimens [0.03%]
接受不同抗逆转录病毒治疗方案的HIV感染孕妇孕期体重增加情况
Marco Floridia,Giulia Masuelli,Beatrice Tassis et al.
Marco Floridia et al.
Background: No published studies have evaluated in pregnant women with HIV weight gain with different antiretroviral drug classes. Methods: ...
Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all? [0.03%]
纠正抗逆转录病毒疗法对肾小管血肌酐分泌影响的估算肾小球滤过率：一刀切合适吗？
Frank A Post,Lisa Hamzah
Frank A Post
Several antiretrovirals including dolutegravir, rilpivirine and cobicistat inhibit tubular creatinine secretion, leading to benign increases in serum creatinine and reductions in estimated glomerular filtration rate (eGFR). This commentary ...
Viral suppression is comparable with 0.5 mg and 1.0 mg daily doses of entecavir in treatment-naive HBV-related decompensated cirrhosis [0.03%]
恩替卡韦治疗乙型肝炎相关失代偿期肝硬化：0.5毫克和1.0毫克每日一次剂量的病毒抑制情况相当
Amit Goel,Sumit Rungta,Prashant Verma et al.
Amit Goel et al.
Background: For patients with HBV infection who have decompensated cirrhosis (DC), a higher dose (1.0 mg/day) of entecavir is recommended than that used for those with compensated disease (0.5 mg/day), though with very li...
Assessing bias introduced in estimated glomerular filtration rate by the inhibition of creatinine tubular secretion from common antiretrovirals [0.03%]
评估由常见抗逆转录病毒药物抑制肌酐管状分泌对估计肾小球滤过率造成的偏倚
Laurence Brunet,Christina Wyatt,Ricky Hsu et al.
Laurence Brunet et al.
Background: Researchers must often rely on creatinine measurements to assess kidney function because direct glomerular filtration rates (GFR) and cystatin-c are rarely measured in routine clinical settings. However, HIV t...
Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study [0.03%]
真实世界临床实践中接受核苷/核苷酸类似物治疗的中国慢性乙型肝炎患者的长期预后：EVOLVE研究的5年结果
Jidong Jia,Jia Shang,Hong Tang et al.
Jidong Jia et al.
Background: In China, the optimal management of individuals living with chronic HBV infection (CHB) remains an unmet need. The EVOLVE Study was a 5-year prospective, longitudinal, observational study that compared the cli...
Observational Study
Antiviral therapy. 2020;25(6):293-304. DOI:10.3851/IMP3372 2020
Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study [0.03%]
南非艾滋病患者接受抗逆转录病毒治疗的病毒载量和病毒抑制记录：多中心队列研究
Tameryn Pillay,Morna Cornell,Matthew P Fox et al.
Tameryn Pillay et al.
Background: Viral suppression in patients on antiretroviral treatment (ART) is critical to reducing HIV transmission and HIV-related mortality. Although many studies have evaluated factors associated with viral suppressio...
Multicenter Study
Antiviral therapy. 2020;25(5):257-266. DOI:10.3851/IMP3371 2020
Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life [0.03%]
基线耐药相关突变可能影响 PegIFN 和利巴韦林治疗失败的慢性丙型肝炎患者的 DAA 治疗效果
Shan Ren,Feili Wei,Yi Jin et al.
Shan Ren et al.
Background: To evaluate the impact of baseline resistance-associated substitutions (RASs) on direct-acting antiviral (DAA) treatment response among pegylated interferon in combination with ribavirin (PR) failing patients ...
Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis [0.03%]
ELBASVIR/GRAZOPREVIR治疗HCV基因1型伴或不伴HIV感染的疗效：HCV核心抗原监测的作用及肝硬度和脂肪变性的改善
Maneerat Chayanupatkul,Salyavit Chittmittraprap,Pornpitra Pratedrat et al.
Maneerat Chayanupatkul et al.
Background: The combination of elbasvir and grazoprevir (EBR/GZR) has been approved for treating HCV infection. This study aimed to evaluate the efficacy of EBR/GZR in terms of sustained virological response (SVR) and imp...